Kingsley has recently joined tranScrip as a Senior Partner. He has twenty-three (23) years post-qualification experience in clinical and pharmaceutical medicine. He has worked in the industry for over ten years and held positions of gradually increasing responsibilities in CROs, biotech and big pharma companies. He has been involved in both exploratory and full development of multiple assets in various therapeutic areas with core concentrations in oncology (AZ), cardiometabolism, immunology, neurosciences and rare diseases (Genzyme).
Kingsley was most recently Medical Director at Avadel Pharmaceuticals where he was the medical and safety lead on a global development program in narcolepsy. He was a significant contributor to other development programs including osimertinib (Tagrisso - AstraZeneca), ex-US lead of the BEACON Study (Reata Pharmaceuticals), etc.
Kingsley graduated from the College of Medicine, University of Port Harcourt, Nigeria (Pharmacology; Medicine & Surgery). He undertook residency training in internal medicine and nephrology and was a Clinical Research Fellow in renal medicine in Manchester Royal Informary and is a fellow of both the International Society for Peritoneal Dialysis (ISPD) and the International Society of Nephrology (ISN). Postgraduate education includes a Postgraduate Diploma in Hhealth Research (Leeds, UK) and MSc in pharmaceutical medicine (Surrey, UK). He is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM). He undertook business/management education at Warwick Business School (MBA) and entrepreneurial education at the Judge Business School in Cambridge UK.
tranScrip is very much looking forward to welcoming him into our development team to which he will bring a strong and varied background.